July 25, 2011

HELIX BIOPHARMA CORP. RECEIVES REGULATORY APPROVAL TO CONDUCT A EUROPEAN PHASE I/II CLINICAL STUDY OF ITS LUNG CANCER DRUG CANDIDATE L-DOS47 (PDF)

AURORA, Ontario, July 25, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of
biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the Central Register of Clinical Trials at the Polish Ministry of Health of its European clinical trial application (“CTA”) to perform the Company’s planned Phase I/II clinical safety, tolerability and preliminary efficacy study of its lung cancer drug candidate, L-DOS47.